国内首个！减重版司美格鲁肽心血管适应症获批上市

Core Viewpoint - The approval of the weight-loss version of semaglutide injection (brand name: NovoYing) for cardiovascular indications marks a significant milestone as it becomes the first GLP-1 class weight-loss drug approved for cardiovascular indications in China [1]. Group 1 - The National Medical Products Administration (NMPA) of China has granted approval for the semaglutide injection to reduce the risk of major cardiovascular adverse events in adults diagnosed with cardiovascular disease and a BMI of ≥27 kg/m² [1].